These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 23335066)

  • 1. The use of a novel MUC1 antibody to identify cancer stem cells and circulating MUC1 in mice and patients with pancreatic cancer.
    Curry JM; Thompson KJ; Rao SG; Besmer DM; Murphy AM; Grdzelishvili VZ; Ahrens WA; McKillop IH; Sindram D; Iannitti DA; Martinie JB; Mukherjee P
    J Surg Oncol; 2013 Jun; 107(7):713-22. PubMed ID: 23335066
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Increased immunogenicity of tumor-associated antigen, mucin 1, engineered to express alpha-gal epitopes: a novel approach to immunotherapy in pancreatic cancer.
    Deguchi T; Tanemura M; Miyoshi E; Nagano H; Machida T; Ohmura Y; Kobayashi S; Marubashi S; Eguchi H; Takeda Y; Ito T; Mori M; Doki Y; Sawa Y
    Cancer Res; 2010 Jul; 70(13):5259-69. PubMed ID: 20530670
    [TBL] [Abstract][Full Text] [Related]  

  • 3. O-glycosylation of MUC1 mucin in prostate cancer and the effects of its expression on tumor growth in a prostate cancer xenograft model.
    Premaratne P; Welén K; Damber JE; Hansson GC; Bäckström M
    Tumour Biol; 2011 Feb; 32(1):203-13. PubMed ID: 20872286
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Circulating anti-MUC1 IgG antibodies as a favorable prognostic factor for pancreatic cancer.
    Hamanaka Y; Suehiro Y; Fukui M; Shikichi K; Imai K; Hinoda Y
    Int J Cancer; 2003 Jan; 103(1):97-100. PubMed ID: 12455059
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Novel Monoclonal Antibody Targets Mucin1 and Attenuates Growth in Pancreatic Cancer Model.
    Wu G; Maharjan S; Kim D; Kim JN; Park BK; Koh H; Moon K; Lee Y; Kwon HJ
    Int J Mol Sci; 2018 Jul; 19(7):. PubMed ID: 29987260
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeting cancer stem cells with an 131I-labeled anti-AC133 monoclonal antibody in human colorectal cancer xenografts.
    Lang J; Lan X; Liu Y; Jin X; Wu T; Sun X; Wen Q; An R
    Nucl Med Biol; 2015 May; 42(5):505-512. PubMed ID: 25669587
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An antibody-drug conjugate targeting a GSTA glycosite-signature epitope of MUC1 expressed by non-small cell lung cancer.
    Pan D; Tang Y; Tong J; Xie C; Chen J; Feng C; Hwu P; Huang W; Zhou D
    Cancer Med; 2020 Dec; 9(24):9529-9540. PubMed ID: 33084221
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antigenic differences between metastatic cells in bone marrow and primary tumours and the anti-MUC1 humoral immune response induced in breast cancer patients.
    Croce MV; Isla-Larrain M; Tur R; Rabassa ME; Segal-Eiras A
    Clin Exp Metastasis; 2004; 21(2):139-47. PubMed ID: 15168731
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In vivo anti-MUC1
    Pichinuk E; Chalik M; Benhar I; Ginat-Koton R; Ziv R; Smorodinsky NI; Haran G; Garbar C; Bensussan A; Meeker A; Guillaume T; Rubinstein DB; Wreschner DH
    Cancer Immunol Immunother; 2020 Jul; 69(7):1337-1352. PubMed ID: 32219500
    [TBL] [Abstract][Full Text] [Related]  

  • 10. MUC-1 aptamer targeted superparamagnetic iron oxide nanoparticles for magnetic resonance imaging of pancreatic cancer in vivo and in vitro experiment.
    Zou Q; Zhang CJ; Yan YZ; Min ZJ; Li CS
    J Cell Biochem; 2019 Nov; 120(11):18650-18658. PubMed ID: 31338877
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Induction of protective and therapeutic anti-pancreatic cancer immunity using a reconstructed MUC1 DNA vaccine.
    Rong Y; Jin D; Wu W; Lou W; Wang D; Kuang T; Ni X; Qin X
    BMC Cancer; 2009 Jun; 9():191. PubMed ID: 19534821
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [The CD133 polyclonal antibody generation and cancer stem cells identification].
    Tian JL; Cai PL; Xia XQ; Li FH; Wang DH; Chen MN
    Sichuan Da Xue Xue Bao Yi Xue Ban; 2011 May; 42(3):422-6. PubMed ID: 21827013
    [TBL] [Abstract][Full Text] [Related]  

  • 13. MUC1 selectively targets human pancreatic cancer in orthotopic nude mouse models.
    Park JY; Hiroshima Y; Lee JY; Maawy AA; Hoffman RM; Bouvet M
    PLoS One; 2015; 10(3):e0122100. PubMed ID: 25815753
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Detection of circulating anti-mucin 1 (MUC1) antibodies in breast tumor patients by indirect enzyme-linked immunosorbent assay using a recombinant MUC1 protein containing six tandem repeats and expressed in Escherichia coli.
    Tang Y; Wang L; Zhang P; Wei H; Gao R; Liu X; Yu Y; Wang L
    Clin Vaccine Immunol; 2010 Dec; 17(12):1903-8. PubMed ID: 20876819
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Analysis of sialyl-Lewis x on MUC5AC and MUC1 mucins in pancreatic cancer tissues.
    Balmaña M; Duran A; Gomes C; Llop E; López-Martos R; Ortiz MR; Barrabés S; Reis CA; Peracaula R
    Int J Biol Macromol; 2018 Jun; 112():33-45. PubMed ID: 29408556
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Radioimmunoscintigraphy of pancreatic cancer in tumor-bearing athymic nude mice using (99m)technetium-labeled anti-KL-6/MUC1 antibody.
    Matsumura K; Niki I; Tian H; Takuma M; Hongo N; Matsumoto S; Mori H
    Radiat Med; 2008 Apr; 26(3):133-9. PubMed ID: 18683568
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Designing a recombinant chimeric construct contain MUC1 and HER2 extracellular domain for prediagnostic breast cancer.
    Gheybi E; Amani J; Salmanian AH; Mashayekhi F; Khodi S
    Tumour Biol; 2014 Nov; 35(11):11489-97. PubMed ID: 25128064
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immune recognition of tumor-associated mucin MUC1 is achieved by a fully synthetic aberrantly glycosylated MUC1 tripartite vaccine.
    Lakshminarayanan V; Thompson P; Wolfert MA; Buskas T; Bradley JM; Pathangey LB; Madsen CS; Cohen PA; Gendler SJ; Boons GJ
    Proc Natl Acad Sci U S A; 2012 Jan; 109(1):261-6. PubMed ID: 22171012
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Aberrantly glycosylated MUC1 is expressed on the surface of breast cancer cells and a target for antibody-dependent cell-mediated cytotoxicity.
    Lavrsen K; Madsen CB; Rasch MG; Woetmann A; Ødum N; Mandel U; Clausen H; Pedersen AE; Wandall HH
    Glycoconj J; 2013 Apr; 30(3):227-36. PubMed ID: 22878593
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Breast cancer humoral immune response: involvement of Lewis y through the detection of circulating immune complexes and association with Mucin 1 (MUC1).
    Isla Larrain M; Demichelis S; Crespo M; Lacunza E; Barbera A; Cretón A; Terrier F; Segal-Eiras A; Croce MV
    J Exp Clin Cancer Res; 2009 Aug; 28(1):121. PubMed ID: 19715603
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.